{"id":2652,"date":"2026-08-21T12:00:00","date_gmt":"2026-08-21T16:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2652"},"modified":"2026-08-21T20:12:20","modified_gmt":"2026-08-22T00:12:20","slug":"china-accepts-opamtistomig-nda-with-priority-review-in-rare-neuroendocrine-carcinoma","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2652","title":{"rendered":"China Accepts Opamtistomig NDA with Priority Review in Rare Neuroendocrine Carcinoma"},"content":{"rendered":"

Company:<\/strong> Nanjing Leads Biolabs · Event Type:<\/strong> NDA Accepted with Priority Review (China NMPA\/CDE) · Asset:<\/strong> Opamtistomig (LBL-024) · Indication:<\/strong> Extrapulmonary Neuroendocrine Carcinoma · Date:<\/strong> August 21, 2026<\/p>\n

\"20260821_Leads_Biolabs_Therapeutic_Indications\"<\/p>\n

Summary<\/h4>\n

China’s Center for Drug Evaluation (CDE) has accepted Nanjing Leads Biolabs’ New Drug Application for opamtistomig (LBL-024), a PD-L1 x 4-1BB bispecific antibody, and granted it Priority Review for extrapulmonary neuroendocrine carcinoma (EP-NEC), an aggressive and rare cancer type with no widely established standard second-line therapy. The filing is supported by a 96-patient single-arm pivotal study; specific efficacy figures were not disclosed in the announcement.<\/p>\n

What Happened<\/h4>\n

Leads Biolabs submitted an NDA for opamtistomig in EP-NEC based on a single-arm pivotal trial of 96 patients, and the CDE has both accepted the filing and designated it for Priority Review, which typically shortens the regulatory timeline for products addressing serious diseases with unmet medical need. Extrapulmonary neuroendocrine carcinoma is a rare and aggressive tumor type arising outside the lungs, and there is currently no broadly established second-line standard of care, which likely factored into the Priority Review designation.<\/p>\n

Deep Analysis<\/h4>\n

Opamtistomig’s mechanism, a bispecific that simultaneously blocks PD-L1 (an immune checkpoint) and agonizes 4-1BB (a T-cell costimulatory receptor), represents a class of “checkpoint plus costimulation” bispecifics designed to overcome the limited efficacy of PD-1\/PD-L1 monotherapy in poorly immunogenic or immune-excluded tumors, which extrapulmonary NEC is often considered to be. The absence of disclosed efficacy data in this announcement is a meaningful gap: a Priority Review acceptance confirms the CDE views the filing as complete and addressing significant unmet need, but it does not by itself validate the magnitude of clinical benefit, which will only become clear when full trial data or the eventual approval label is published.<\/p>\n

The single-arm design of the pivotal study is also worth flagging. Single-arm registrational trials are more common in rare, aggressive cancers where randomization against a weak standard of care may be considered unethical or impractical, but they inherently provide a weaker efficacy signal than randomized comparisons, since response rates and duration of response are being benchmarked against historical controls rather than a concurrent comparator arm.<\/p>\n

Company and Product Background<\/h4>\n

Nanjing Leads Biolabs is a China-based biopharmaceutical company focused on bispecific and multispecific antibody therapeutics for oncology. Opamtistomig (LBL-024) combines PD-L1 blockade with 4-1BB agonism in a single molecule, a design intended to concentrate costimulatory signaling within the tumor microenvironment (where PD-L1 is engaged) rather than systemically, which can reduce the liver toxicity that has historically limited standalone 4-1BB agonist antibodies in the clinic.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n\n
Factor<\/th>\nAssessment<\/th>\n<\/tr>\n
Regulatory Status<\/td>\nNDA accepted by China CDE with Priority Review<\/td>\n<\/tr>\n
Indication<\/td>\nExtrapulmonary neuroendocrine carcinoma (EP-NEC)<\/td>\n<\/tr>\n
Pivotal Trial Design<\/td>\nSingle-arm, 96 patients<\/td>\n<\/tr>\n
Efficacy Data<\/td>\nNot disclosed in this announcement<\/td>\n<\/tr>\n
Unmet Need<\/td>\nNo broadly established second-line standard of care<\/td>\n<\/tr>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> Priority Review acceptance in a rare cancer with no established second-line standard signals meaningful regulatory recognition of unmet need, and the PD-L1 x 4-1BB mechanism addresses a real biological gap left by checkpoint monotherapy.<\/p>\n

Bear case:<\/strong> Undisclosed efficacy data from a single-arm study leaves the actual clinical benefit unverified, and single-arm registrational data is inherently a weaker evidentiary basis than a randomized trial.<\/p>\n

InSilens Take<\/h4>\n

This is a regulatory-process signal, not yet a clinical-efficacy one. Priority Review status confirms the CDE sees a credible unmet-need case, but the real read on opamtistomig’s value will come when the underlying response and survival data are disclosed, likely around approval or at a subsequent medical conference.<\/p>\n

Signal Assessment<\/h4>\n

Importance:<\/strong> 4\/5 · Direction:<\/strong> Uncertain · Confidence:<\/strong> Low<\/p>\n","protected":false},"excerpt":{"rendered":"

China’s Center for Drug Evaluation (CDE) has accepted Nanjing Leads Biolabs’ New Drug Application for opamtistomig (LBL-024), a PD-L1 x 4-1BB bispecific antibody, and granted it Priority Review for extrapulmonary neuroendocrine carcinoma (EP-NEC), an…<\/p>\n","protected":false},"author":1,"featured_media":2660,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[411,413,412],"class_list":["post-2652","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-nanjing-leads-biolabs","tag-neuroendocrine-carcinoma","tag-opamtistomig"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2652","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2652"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2652\/revisions"}],"predecessor-version":[{"id":2666,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2652\/revisions\/2666"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2660"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2652"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2652"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2652"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}